Comparison of rituximab-treated cases and controls. (A) Incidence of corticosteroid-requiring chronic GVHD. Solid line, incidence of corticosteroid-requiring chronic GVHD, rituximab-treated cases; dashed line, incidence of corticosteroid-requiring chronic GVHD, untreated controls. (B) Nonrelapse mortality and disease recurrence. Dotted line, incidence of relapse, rituximab-treated cases; solid line, incidence of nonrelapse mortality, rituximab-treated cases; dot-dash line, incidence of relapse, untreated controls; dashed line, of nonrelapse mortality, untreated controls. (C) Overall survival. Solid line, rituximab-treated cases; dashed, untreated controls.